advertisement

Baxter reports sales gain

DEERFIELD - Baxter International Inc. reported worldwide sales in the first quarter totaling approximately $2.9 billion, an increase of 5%. Sales in the U.S. totaled $1.2 billion, decreasing 3%.

Performance in the first quarter was driven by Acute Therapies category, which delivered significant growth reflecting sustained higher levels of product demand due to the ongoing COVID-19 pandemic. Biopharma Solutions category also delivered double-digit growth driven by multiple collaborations to help manufacture COVID-19 vaccines on a contract basis, the global medical products company said.

"Baxter's medically essential products are fundamental to health care, and many have proven pivotal in the fight against COVID-19," said José (Joe) E. Almeida, chairman, president and chief executive officer. "Our life-sustaining portfolio, broad geographic reach and the ongoing momentum of our business transformation are all keys to our resilience."

Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.